Abstract
We monitored the immune response after liver transplantation in 20 patients by measuring the serum levels of soluble interleukin-2 receptor (sIL-2R), soluble CD8 (sCD8), serum amyloid-A protein (SAA), and tumor necrosis factor-α (TNF-α). In six patients data were available to extend the follow-up period to one year. In all patients mean sIL-2R levels increased in the first month after liver transplantation, and subsequently decreased to values similar to pre-OLT ones, while SAA mean levels rose in the first week after OLT only in patients with rejection. sCD8 levels did not significantly rise after OLT, and TNF-α was undetectable in most cases. During episodes of rejection, rejector patients had significantly higher levels of sIL-2R, sCD8, and SAA than stable (without complications) patients. Conversely, no significant difference between rejectors and patients with other complications existed for any of the markers studied. These results diminish the importance of these serum markers of immune activation as laboratory tools in the differential diagnosis of acute rejection from other complications. However, sIL-2R, SAA, and sCD8 levels correlated with the histological grade of rejection and therefore can be utilized to monitor patients with an established diagnosis of acute rejection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rego J, Prevost F, Rumeau JL, Modesto A, Fourtanier G, Durand D, Suc JM, Ohayon E, Ducos J: Hyperacute rejection after ABO-incompatible orthotopic liver transplantation. Transplant Proc 19:4589–4590, 1987
Calne RY, Sells RA, Pena JR, Davis DR, Millard PR: Induction of immunological tolerance by porcine liver allograft. Nature 223:472–476, 1969
Bismuth H: Liver transplantation: the Paul Brousse experience. Transplant Proc 20(suppl 1):486–488, 1988
Starzl TE, Iwatsuki S, Shaw, BW Jr, Gordon RD, Esquivel CO: Immunosuppression and other nonsurgical factors in the improved results of liver transplantation. Semin Liver Dis 5:334–339, 1985
Adams DH, Hubscher SG, Wang L, Elias E, Neuberger JM: Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet I:469–471, 1989
Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RAF: Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 47:77–81, 1989
Maury CPJ, Höckerstedt K, Lautenschlager I, Scheinin TM: Monitoring of high density lipoprotein-associated amyloid A protein after liver transplantation. Transplant Proc 19:3825–3826, 1987
Goldberger G, Bing DH, Sipe JD, Rits M, Colten HR: Transcriptional regulation of genes, encoding the acute-phase proteins CRP, SAA and C3. J Immunol 138:3967–3971, 1987
Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL: Soluble CD8 during T cell activation. J Immunol 142:2230–2236, 1989
Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316:379–385, 1987
Maury CPJ: Teppo A-M Raised serum levels of cachectin/ tumor necrosis factor in renal allograft rejection. J Exp Med 166:1132–1137, 1987
Williams JW, Peters TG, Vera SR, Britt LG, Van Voorst SJ, Haggitt RC: Biopsy-directed immunosuppression following hepatic transplantation in man. Transplantation 39:589–596, 1985
Zuckerman SH, Surprenant YM: Simplified micro ELISA for the quantitation of murine serum amyloid A protein. J Immunol Methods 92:37–42, 1986
Godenir NL, Jeenah MS, Coetzee GA, Van der Westhuyzen DR, Strachan AF, De Beer FC: Standardisation of the quantitation of serum amyloid A protein (SAA) in human serum. J Immunol Methods 83:217–223, 1985
Godfrey K: Comparing the means of several groups. N Engl J Med 313:1450–1455, 1985
Meliconi R, Uguccioni MG, Lalli E, Nesci S, Delfini C, Paradisi O, Lucarelli G, Gasbarrini G, Facchini A: Increased serum levels of TNF-α in β-thalassemia: The effect of bone marrow transplantation. J Clin Pathol 45:61–65, 1992
Granelli-Piperno A, Andrus J, Steinman RM: Lymphokine and nonlymphokine mRNA levels in stimulated human T cell: Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med 163:922–937, 1986
Metcalfe S: Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation 38:161–164, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lalli, E., Meliconi, R., Conte, R. et al. Serum markers of immune activation and liver allograft rejection. Digest Dis Sci 37, 1116–1120 (1992). https://doi.org/10.1007/BF01300296
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01300296